Use of TCC capacity assay to monitor complement inhibition in patients treated with eculizumab

Trial Profile

Use of TCC capacity assay to monitor complement inhibition in patients treated with eculizumab

Completed
Phase of Trial: Phase II

Latest Information Update: 21 Oct 2015

At a glance

  • Drugs Eculizumab (Primary)
  • Indications Haemolytic uraemic syndrome
  • Focus Pharmacodynamics
  • Most Recent Events

    • 21 Oct 2015 New trial record
    • 18 Sep 2015 Results presented at Joint 55th Interscience Conference on Antimicrobial Agents and Chemotherapy and 28th International Congress of Chemotherapy.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top